Table 4.
Baseline clinical data and modified clot lysis assay (mCLA)* parameters according to long-term functional outcomes at 90 days post-event.
| mRS 0–1 (n = 15) | mRS 2–5 (n = 32) | mRS 6 (n = 39) | p | |
|---|---|---|---|---|
| Age, y, mean ± SD | 64 ± 12 | 67 ± 13 | 71 ± 10 | 0.054 |
| Male sex, n (%) | 10 (67) | 21 (66.0) | 28 (72) | 0.920 |
| Stroke severity on admission, NIHSS, median (IQR) | 5 (4–6) | 13 (10–17) | 19 (15–23) | <0.0001 |
| <0.0001§ | ||||
| <0.001# | ||||
| 0.015† | ||||
| Cerebrovascular risk factors, n (%) | ||||
| Arterial hypertension | 13 (87) | 32 (100) | 39 (100) | 0.060 |
| Atrial fibrillation | 0 (0) | 5 (16) | 5 (13) | 0.283 |
| Diabetes mellitus | 6 (40) | 12 (38) | 20 (51) | 0.541 |
| Hyperlipidemia | 11 (73) | 14 (44) | 23 (59) | 0.095 |
| Active smoker | 5 (33) | 6 (19) | 4 (10) | 0.109 |
| BMI, kg/m2, median (IQR) | 23.6 (21.5–26.0) | 30.2 (25.0–33.2) | 27.1 (25.4–31.6) | 0.012 |
| 0.037§ | ||||
| 0.011# | ||||
| Laboratory measurements on admission, median (IQR) | ||||
| INR | 0.96 (0.94–0.99) | 0.95 (0.91–0.99) | 1.01 (0.94–1.21) | 0.029 |
| 0.033† | ||||
| APTT, s | 27.6 (25.7–29.6) | 28.0 (24.8–30.4) | 27.9 (25.4–33.3) | 0.822 |
| WBC, G/L | 6.9 (6.5–9.4) | 8.8 (7.6–12.3) | 8.8 (6.7–11.4) | 0.315 |
| Platelet count, G/L | 250 (158–273) | 253 (209–288) | 200 (168–243) | 0.032 |
| 0.027# | ||||
| Serum glucose, mmol/L | 7.4 (5.5–11.2) | 7.3 (6.0–9.8) | 7.7 (6.3–11.2) | 0.563 |
| hsCRP, mg/L | 1.5 (0.7–4.1) | 4.2 (1.3–8.1) | 2.7 (1.2–7.0) | 0.193 |
| Creatinine, μmol/L | 70 (54–88) | 68 (55–83) | 72 (64–88) | 0.478 |
| Fibrinogen, mg/ml | 4.0 (3.2–4.3) | 3.8 (3.3–4.6) | 3.5 (3.0–4.5) | 0.339 |
| Plasminogen activity (%) | 111 (93–123) | 113 (100–132) | 107 (103–117) | 0.456 |
| α2-plasmin inhibitor activity (%) | 103 (99–109) | 112 (103–115) | 105 (96–114) | 0.135 |
| Factor XIII activity (%) | 160 (138–175) | 174 (160–180) | 165 (141–178) | 0.071 |
| mCLA parameters | ||||
| Maximal absorbance (OD) | 1.37 (1.3–1.6) | 1.50 (1.4–1.6) | 1.42 (1.3–1.6) | 0.454 |
| Time to maximal absorbance (min) | 15.0 (12.0–16.5) | 10.5 (8.0–14.0) | 9.5 (7.5–14.5) | 0.039 |
| 0.047§ | ||||
| 10%CLT (min) | 36.0 (22.5–51.0) | 23.5 (17.8–36.0) | 22.5 (18.0–30.5) | 0.027 |
| 0.032§ | ||||
| 50%CLT (min) | 48.0 (42.0–63.0) | 32.0 (28.0–49.5) | 34.5 (27.0–45.0) | 0.041 |
| 0.043§ | ||||
| 90%CLT (min) | 81.0 (68.0–90.0) | 75.0 (69.0–85.5) | 75.0 (68.0–87.0) | 0.490 |
| CLA AUC (OD*min) | 29.4 (23.7–34.5) | 24.6 (18.8–29.7) | 24.4 (19.5–29.3) | 0.149 |
mCLA is performed in the presence of cell-free DNA and histones. Data are means ± SD or medians (interquartile ranges). 10%CLT, 10% clot lysis time; 50%CLT, 50% clot lysis time; 90%CLT, 90% clot lysis time; APTT, activated partial thromboplastin time; BMI, body mass index; hsCRP, high sensitivity C-reactive protein measurement; CLA, clot lysis time; CLA AUC, clot lysis assay area under the curve; INR, international normalized ratio; mRS, modified Rankin Scale.
mRS 0–1 vs. mRS 6 (ANOVA, Bonferroni post-hoc-test or Kruskal-Wallis, Dunn's post-hoc-test).
mRS 2–5 vs. mRS 6 (ANOVA, Bonferroni post-hoc-test).
mRS 0–1 vs. mRS 2-5 (ANOVA, Bonferroni post-hoc-test or Kruskal-Wallis, Dunn's post-hoc-test).